Serial Gray Scale Intravascular Ultrasound Findings in Late Drug-Eluting Stent Restenosis

Hakim, Diaa; Mintz, Gary S.; Sanidas, Elias; Rusinova, Reni; Weisz, Giora; Leon, Martin B.; Moses, Jeffery W.; Stone, Gregg W.; Maehara, Akiko

doi:10.1016/j.amjcard.2012.11.027

Cited by 15 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, they may be more calcified. Hakim et al showed a 20% rate of neointimal calcification in 54 late drug-eluting stent restenotic lesions using serial gray scale intravascular ultrasound (11). Third, the presence of a prior stent could interfere with equipment advancement through the CTO.…”

Section: Discussionmentioning

confidence: 99%

The efficacy of “hybrid” percutaneous coronary intervention in chronic total occlusions caused by in‐stent restenosis: Insights from a US multicenter registry

Christopoulos

Karmpaliotis

Alaswad

et al. 2014

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives To examine the success and complication rates in percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) caused by in-stent restenosis (ISR). Background PCI for in-stent total occlusive disease has traditionally been associated with low success rates. We sought to examine angiographic and procedural outcomes of patients who underwent CTO PCI due to ISR using the novel “hybrid” algorithm, and compare them with patients with de novo CTOs. Methods We examined 521 consecutive patients who underwent CTO PCI at 5 high volume PCI centers in the United States using the “hybrid” approach. Clinical, angiographic and procedural outcomes were compared between CTOs due to ISR and de novo CTOs. Results The target CTO was due to ISR in 57 of 521 patients (10.9%). Compared to patients with de novo CTOs, those with CTO due to ISR had higher frequency of diabetes (56.1% vs. 39.6%, p=0.02) and less calcification (5.3% vs. 16.2%, p<0.001), but longer occlusion length [38 (29-55) vs. 30 (20-51), p=0.04]. Technical success in the ISR and de novo group was 89.4% vs. 92.5% (p=0.43), respectively; procedural success was 86.0% vs. 90.3% (p=0.31), respectively; and the incidence of major adverse cardiac events was 3.5% vs. 2.2% (p=0.63), respectively. Conclusions Use of the “hybrid” approach to CTO PCI was associated with similarly high procedural success and similarly low major complication rates in patients with de novo and ISR CTOs.

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy of “hybrid” percutaneous coronary intervention in chronic total occlusions caused by in‐stent restenosis: Insights from a US multicenter registry

Christopoulos

Karmpaliotis

Alaswad

et al. 2014

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Serial IVUS acquisitions were not available in the present study, but recently two IVUS studies showed chronic stent recoil to be a rare cause of in-stent restenosis. (38,39) As stent dimensions rarely change over time, the MSA of the original stent implantation procedure still has the greatest impact on subsequent interventions to treat DES restenosis.…”

Section: Accepted M Manuscriptmentioning

confidence: 99%

Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in-stent restenosis after drug-eluting or bare-metal stent implantation. The Nordic Intravascular Ultrasound Study (NIVUS)

Jensen

Vikman

Antonsen

et al. 2017

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

show abstract

“…Drug-eluting stents (DES) have also been used to combat CVD but are less effective for patients with T2DM (18, 32). Sirolimus and paclitaxel (antiproliferative agents) used with early-generation DES impede healing of the intima after implantation, thereby inhibiting coverage of the stent linkages by endothelial cells (ECs) and making the vessel more prone to late thrombosis (20,22). Newer generation DES with zotarolimus and everolimus more favorably inhibit the proliferation of smooth muscle cells (SMC) and inflammatory cells (26), but improvements in mortality, myocardial infarction, stent thrombosis, and target lesion revascularization afforded to patients with normoglycemia with these newer DES have not translated to patients with diabetes (11,44).…”

mentioning

confidence: 99%

Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats

Wang

Weihrauch

Kersten

et al. 2015

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Mechanisms of restenosis in type 2 diabetes mellitus (T2DM) are incompletely elucidated, but advanced glycation end-product (AGE)-induced vascular remodeling likely contributes. We tested the hypothesis that AGE-related collagen cross-linking (ARCC) leads to increased downstream vascular resistance and altered in-stent hemodynamics, thereby promoting neointimal hyperplasia (NH) in T2DM. We proposed that decreasing ARCC with ALT-711 (Alagebrium) would mitigate this response. Abdominal aortic stents were implanted in Zucker lean (ZL), obese (ZO), and diabetic (ZD) rats. Blood flow, vessel diameter, and wall shear stress (WSS) were calculated after 21 days, and NH was quantified. Arterial segments (aorta, carotid, iliac, femoral, and arterioles) were harvested to detect ARCC and protein expression, including transforming growth factor-β (TGF-β) and receptor for AGEs (RAGE). Downstream resistance was elevated (60%), whereas flow and WSS were significantly decreased (44% and 56%) in ZD vs. ZL rats. NH was increased in ZO but not ZD rats. ALT-711 reduced ARCC and resistance (46%) in ZD rats while decreasing NH and producing similar in-stent WSS across groups. No consistent differences in RAGE or TGF-β expression were observed in arterial segments. ALT-711 modified lectin-type oxidized LDL receptor 1 but not RAGE expression by cells on decellularized matrices. In conclusion, ALT-711 decreased ARCC, increased in-stent flow rate, and reduced NH in ZO and ZD rats through RAGE-independent pathways. The study supports an important role for AGE-induced remodeling within and downstream of stent implantation to promote enhanced NH in T2DM.

show abstract

Serial Gray Scale Intravascular Ultrasound Findings in Late Drug-Eluting Stent Restenosis

Cited by 15 publications

References 21 publications

The efficacy of “hybrid” percutaneous coronary intervention in chronic total occlusions caused by in‐stent restenosis: Insights from a US multicenter registry

The efficacy of “hybrid” percutaneous coronary intervention in chronic total occlusions caused by in‐stent restenosis: Insights from a US multicenter registry

Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in-stent restenosis after drug-eluting or bare-metal stent implantation. The Nordic Intravascular Ultrasound Study (NIVUS)

Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats

Contact Info

Product

Resources

About